Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Brief: eFFECTOR Receives U.S. FDA Fast Track Designation For Zotatifin In Combination With Fulvestrant And Abemaciclib For Treatment Of Er+/Her2- Advanced Metastatic Breast Cancer

Nov 28 (Reuters) - eFFECTOR Therapeutics Inc  EFTR.O :
    * EFFECTOR RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
ZOTATIFIN
IN COMBINATION WITH FULVESTRANT AND ABEMACICLIB FOR TREATMENT OF
ER+/HER2- ADVANCED METASTATIC BREAST CANCER

Source text for Eikon:  ID:nGNXqFXwL 
Further company coverage:  EFTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news